PMID- 17924870
OWN - NLM
STAT- MEDLINE
DCOM- 20080225
LR  - 20181201
IS  - 1462-8902 (Print)
IS  - 1462-8902 (Linking)
VI  - 9
IP  - 6
DP  - 2007 Nov
TI  - Comparison of the antidiabetic effects of brain-derived neurotrophic factor and 
      thiazolidinediones in obese diabetic mice.
PG  - 879-88
AB  - AIMS: Brain-derived neurotrophic factor (BDNF) ameliorates glucose metabolism in 
      obese diabetic db/db mice. The antidiabetic effect of BDNF is dependent on plasma 
      insulin levels, and BDNF enhances insulin action by modulating insulin signalling 
      in peripheral tissues. The aim of the study was to compare the antidiabetic 
      effects of BDNF with those of thiazolidinediones (TZDs), which are 
      insulin-sensitizing agents, through evaluation of the effects of BDNF and TZDs on 
      glucose metabolism, energy expenditure, pancreatic function and hepatic steatosis 
      in db/db mice. METHODS: The effects of BDNF, pioglitazone and rosiglitazone on 
      blood glucose concentration, body weight and pancreatic insulin and glucagon 
      contents and the effects of BDNF and troglitazone treatment for 3 weeks on blood 
      glucose concentration, body and liver weights and histological liver images were 
      examined in db/db mice. Furthermore, since BDNF reduces food intake in obese 
      hyperphagic diabetic mice, the effects of BDNF treatment for 3 weeks on blood 
      glucose concentration, body weight, fat pad and liver weights and rectal 
      temparature in db/db mice were compared with those of troglitazone under pair-fed 
      conditions. RESULTS: BDNF, pioglitazone and rosiglitazone all ameliorated 
      hyperglycaemia in db/db mice, but BDNF increased the pancreatic insulin content 
      more effectively than pioglitazone and rosiglitazone. The pancreatic glucagon 
      content decreased with BDNF, but increased with pioglitazone and rosiglitazone 
      compared with vehicle, and body weight and liver weight increased with 
      troglitazone, but decreased with BDNF compared with vehicle. Histological 
      analysis of the liver showed that BDNF treatment reduced the massive 
      vacuolization observed with vehicle, whereas troglitazone worsened the 
      vacuolization. Body weight, fat pad and liver weights in BDNF-treated mice were 
      significantly lower than those in pair-fed troglitazone-treated db/db mice, and 
      rectal temperature in BDNF-treated mice was significantly higher than that in 
      pair-fed troglitazone-treated mice, suggesting that BDNF enhances energy 
      expenditure. CONCLUSIONS: These data suggest that compared with TZDs, BDNF 
      potently ameliorates pancreatic dysfunction, fatty liver and energy expenditure, 
      thereby exerting favourable antidiabetic effects in type 2 diabetic mice.
FAU - Yamanaka, M
AU  - Yamanaka M
AD  - Pharmacology Research Laboratories, Drug Research Division, Dainippon Sumitomo 
      Pharma Co., Ltd, Osaka, Japan. matsuo-taiji@ds-pharma.co.jp
FAU - Itakura, Y
AU  - Itakura Y
FAU - Tsuchida, A
AU  - Tsuchida A
FAU - Nakagawa, T
AU  - Nakagawa T
FAU - Noguchi, H
AU  - Noguchi H
FAU - Taiji, M
AU  - Taiji M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Blood Glucose)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazolidinediones)
RN  - 05V02F2KDG (Rosiglitazone)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Animals
MH  - Blood Glucose/analysis/drug effects/metabolism
MH  - Brain-Derived Neurotrophic Factor/pharmacology/*therapeutic use
MH  - Diabetes Mellitus, Experimental/drug therapy
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Energy Metabolism
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - Mice
MH  - Mice, Obese
MH  - Pioglitazone
MH  - Rosiglitazone
MH  - Thiazolidinediones/pharmacology/*therapeutic use
EDAT- 2007/10/11 09:00
MHDA- 2008/02/26 09:00
CRDT- 2007/10/11 09:00
PHST- 2007/10/11 09:00 [pubmed]
PHST- 2008/02/26 09:00 [medline]
PHST- 2007/10/11 09:00 [entrez]
AID - DOM675 [pii]
AID - 10.1111/j.1463-1326.2006.00675.x [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2007 Nov;9(6):879-88. doi: 10.1111/j.1463-1326.2006.00675.x.